Key result
Rituximab administration in rheumatoid arthritis patients significantly reduced anti-AAV2 IgG levels (p=0.0371), though neutralizing antibody titers dropped below 1:5 in only a minority of subjects.
Why the study?
Does B-cell depletion with rituximab reduce anti-AAV neutralizing antibody titers in patients with rheumatoid arthritis?
Observational (n=39)
No
Does B-cell depletion with rituximab reduce anti-AAV neutralizing antibody titers in patients with rheumatoid arthritis?
p-value: p=0.0371
No takes yet. Share an insight, caveat, or question.
May support intra-articular AAV gene therapy in RA despite systemic NAbs; leaves open transduction efficacy in patients.
Mingozzi et al. (2012) conducted an observational in Rheumatoid arthritis (n=39). Rituximab vs. Baseline (pre-rituximab administration) was evaluated on Change in anti-AAV2 total IgG levels at 24 weeks post-rituximab (p=0.0371). Rituximab administration in rheumatoid arthritis patients significantly reduced anti-AAV2 IgG levels (p=0.0371), though neutralizing antibody titers dropped below 1:5 in only a minority of subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: